'Psyched': FDA Expands Indications For Ketamine, MindMed Launches Subsidiary, John Hopkins Begins 'Real-World' Study
FDA Expands Psychiatric Indications For Nasal Spray Ketamine
Last week, the FDA approved suicidal tendencies as additional qualifying symptoms for the application of Spravato, a ketamine nasal spray used in psychiatric treatment.
